Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT00378911 · ClinicalTrials.gov registry record · Phase 2
Sunitinib in Treating Patients With Recurrent or Persistent Leiomyosarcoma of the Uterus
A Phase 2 study of Uterine Leiomyosarcoma and Recurrent Uterine Sarcoma, sponsored by National Cancer Institute (NCI).
- Completed
- Registry status
- Phase 2
- Development phase
- 44
- Enrollment target
- 1
- Study location
NCT00378911 is a Phase 2 study of Uterine Leiomyosarcoma and Recurrent Uterine Sarcoma that has completed, run by National Cancer Institute (NCI). The registered enrollment target is 44 participants, above the 35-participant average among 3 other Uterine Leiomyosarcoma trials with a reported enrollment target (26% higher). The trial reports 1 study location across 1 state.
The verdict
NCT00378911, a Phase 2 study of Uterine Leiomyosarcoma and Recurrent Uterine Sarcoma, has completed, sponsored by National Cancer Institute (NCI).
- COMPLETED
- Registry status
- Phase 2
- Development phase
- 44 participants
- Enrollment target
- 1
- Study location
Study Summary
This phase II trial is studying how well sunitinib works in treating patients with recurrent or persistent leiomyosarcoma of the uterus. Sunitinib may stop the growth of tumor cells by blocking some of the enzymes needed for cell growth and by blocking blood flow to the tumor.
Conditions Studied
Interventions
- DRUG sunitinib malate
Study Locations (1)
Pennsylvania
- Gynecologic Oncology Group - Philadelphia
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 44 participants |
| Start Date | 2006-10 |
| Est. Completion | 2010-01 |
| Phase | Phase 2 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT00378911
The ClinicalTrials.gov registry entry for NCT00378911 describes a study currently listed as completed, categorized as Phase 2. The registered enrollment target is 44 participants, a figure that helps gauge the scale of data the investigators plan to collect, above the 35-participant average among 3 other Uterine Leiomyosarcoma trials with a reported enrollment target (26% higher). The listed sponsor is National Cancer Institute (NCI), which has 3,257 total studies on file at ClinicalTrials.gov.
The record links to 2 conditions, with Uterine Leiomyosarcoma appearing as the primary indexed condition, and to 1 intervention - of which sunitinib malate is the first listed.
NCT00378911 reports 1 study location spanning 1 distinct geographic area - top geographies include Pennsylvania.
Frequently Asked Questions
What is clinical trial NCT00378911 about?
NCT00378911 is a clinical study titled "Sunitinib in Treating Patients With Recurrent or Persistent Leiomyosarcoma of the Uterus". This phase II trial is studying how well sunitinib works in treating patients with recurrent or persistent leiomyosarcoma of the uterus. Sunitinib may stop the growth of tumor cells by blocking some of the enzymes needed for cell growth and by blocking blood flow to the tumor.
What is the current status of trial NCT00378911?
This trial is currently completed. It is a Phase 2 study. The enrollment target is 44 participants. The study started on 2006-10. Estimated completion is 2010-01.
What conditions does trial NCT00378911 study?
This clinical trial studies the following conditions: Uterine Leiomyosarcoma, Recurrent Uterine Sarcoma.
What interventions are being tested in trial NCT00378911?
The interventions under investigation include: sunitinib malate (DRUG).
Who is sponsoring clinical trial NCT00378911?
This trial is sponsored by National Cancer Institute (NCI), which has 3,257 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT00378911 being conducted?
This trial has 1 study location across Pennsylvania. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Uterine Leiomyosarcoma
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
-
Letrozole in Uterine Leiomyosarcoma
RECRUITING · Phase 2
-
Phase II Decentralized Pragmatic Trial of Adjuvant Doxorubicin - Trabectedin Chemotherapy in uLMS
RECRUITING · Phase 2
-
CytoreductiveSurgery & HIPEC w/Gemcitabine+Chemotherapy w/Dacarbazine in Uterine Leiomyosarcoma
ACTIVE NOT RECRUITING · Phase 2
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.